PFE logo

Pfizer Inc.

PFE
Healthcare|Drug Manufacturers - General|US
$29.39
-0.06 (-0.20%)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50

Analyst Consensus

Hold40 analysts
Strong Buy
0
Buy
16
Hold
23
Sell
1
Strong Sell
0
Consensus Target
$31.13
Implied Upside
+5.9%
Low Target
$26.00
High Target
$40.00

Price Target Trend

Last Month
$37.00
2 targets · +26% vs price
Last Quarter
$33.00
5 targets · +12% vs price
Last Year
$28.95
20 targets · -1% vs price
All Time
$40.85
66 targets · +39% vs price

Rating Trend

Dec 25
10 buy · 15 hold · 1 sell
Jan 26
10 buy · 15 hold · 1 sell
Feb 26
10 buy · 16 hold · 3 sell
Mar 26
10 buy · 16 hold · 3 sell
Apr 26
11 buy · 15 hold · 3 sell
May 26
11 buy · 15 hold · 3 sell
Jun 26
11 buy · 16 hold · 3 sell
Jul 26
11 buy · 16 hold · 2 sell
Aug 26
10 buy · 16 hold · 2 sell
Sep 26
10 buy · 16 hold · 2 sell
Oct 26
10 buy · 17 hold · 2 sell
Nov 26
9 buy · 17 hold · 2 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 6, 2026FBN Securities$34.00(+16%)$29.31StreetInsider
Nov 4, 2026Argus ResearchDavid Toung$40.00(+30%)$30.79StreetInsider
Oct 8, 2026Cantor FitzgeraldCarter Gould$28.00(+0%)$28.00StreetInsider
Oct 6, 2026Scotiabank$33.00(+21%)$27.30TheFly
Sep 10, 2026HSBC$30.00(+8%)$27.78TheFly
Aug 7, 2026Guggenheim$31.00(+18%)$26.20TheFly
Jul 6, 2026HSBC$28.00(+15%)$24.32TheFly
May 27, 2026UBSMichael Yee$27.00(+2%)$26.34StreetInsider
May 14, 2026Wolfe ResearchAlexandria Hammond$26.00(+0%)$25.96TheFly
Mar 17, 2026Morgan StanleyTerence Flynn$27.00(-0%)$27.05StreetInsider
Mar 9, 2026BMO CapitalEvan David Seigerman$30.00(+13%)$26.48StreetInsider
Feb 24, 2026RBC CapitalTrung Huynh$25.00(-8%)$27.14StreetInsider
Feb 19, 2026BarclaysEmily Field$25.00(-7%)$26.86TheFly
Feb 12, 2026DaiwaNarumi Nakagiri$27.00(-3%)$27.73TheFly
Jan 27, 2026Cantor Fitzgerald$27.00(+4%)$25.88TheFly
Jan 6, 2026UBS$25.00(-2%)$25.43TheFly
Dec 17, 2025Wolfe ResearchAlexandria Hammond$24.00(-6%)$25.53StreetInsider
Dec 12, 2025Morgan Stanley$28.00(+8%)$25.89TheFly
Dec 10, 2025HSBCRajesh Kumar$29.00(+14%)$25.33TheFly
Nov 24, 2025Guggenheim$35.00(+39%)$25.17TheFly

Recent Rating Actions

FirmActionRatingDate
Freedom BrokermaintainBuyNov 6, 2026
GuggenheimmaintainBuyNov 5, 2026
UBSmaintainNeutralNov 4, 2026
ScotiabankmaintainSector OutperformNov 4, 2026
CitigroupmaintainNeutralNov 4, 2026
RBC CapitalmaintainSector PerformNov 4, 2026
JP MorganmaintainNeutralOct 9, 2026
Cantor FitzgeraldmaintainNeutralOct 8, 2026
ScotiabankmaintainSector OutperformOct 6, 2026
HSBCmaintainHoldSep 10, 2026
GuggenheimmaintainBuyAug 7, 2026
BMO CapitalmaintainOutperformJul 13, 2026
GuggenheimmaintainBuyJul 13, 2026
B of A SecuritiesmaintainNeutralJul 10, 2026
JP MorganmaintainNeutralJul 8, 2026
Cantor FitzgeraldmaintainNeutralJul 6, 2026
HSBCdowngradeBuy →HoldJul 6, 2026
RBC CapitalupgradeUnderperform →Sector PerformJun 10, 2026
CitigroupmaintainNeutralApr 29, 2026
RBC CapitalmaintainUnderperformApr 20, 2026
UBSmaintainNeutralApr 13, 2026
Morgan StanleymaintainEqual WeightApr 10, 2026
B of A SecuritiesmaintainNeutralApr 9, 2026
GuggenheimmaintainBuyMar 24, 2026
HSBCmaintainBuyMar 17, 2026

Earnings History

Next report: Feb 2, 2027 · EPS est. $0.69
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 3, 2026$0.87$0.73$16.58B$15.85B
Aug 4, 2026$0.77$0.68$15.03B$14.40B
May 5, 2026$0.75$0.72$14.45B$13.84B
Feb 3, 2026$0.66$0.57$17.56B$16.85B
Nov 4, 2025$0.87$0.63$16.65B$16.50B
Aug 5, 2025$0.78$0.58$14.65B$13.56B
Apr 29, 2025$0.92$0.67$13.71B$13.92B
Feb 4, 2025$0.63$0.47$17.76B$17.35B

News

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

Eli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share. Pfizer had to drop its GLP-1 drug candidate, but quickly pivoted by acquiring a new GLP-1 drug still in development.

Nov 7, 2026fool.com
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market

They are so much more than just dividend stocks.

Nov 6, 2026fool.com
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher

A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.

Nov 6, 2026247wallst.com
November Buy: 6 IDEAL S&P 500 'Safer' Dividend Dogs

Six S&P 500 'safer' high-yield dividend stocks—Regions Financial, Ford, AT&T, Pfizer, Verizon, VICI Properties—currently offer attractive buy signals based on free cash flow yields. Analyst projections for the top ten S&P 500 dividend dogs indicate potential net gains of 14.54% to 40.07% by November 2027, with an average estimated gain of 27.42%. Dividend dog strategy favors stocks where annual dividends from $1,000 invested exceed single-share prices and free cash flow yields surpass dividend y…

Nov 6, 2026seekingalpha.com
Diamond Hill Large Cap Fund Q3 2026 Portfolio Update

The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.

Nov 6, 2026seekingalpha.com
5 High-Yield Dividend Stocks That Could Hold Up When the Market Falls

Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that could change its income story.

Nov 6, 2026247wallst.com
Buy, Sell, or Hold? Friday’s Top Upgrades and Downgrades: Becton Dickinson, BJ’s Wholesale Club, Cogent Communications, Fervo Energy, JinkoSolar, Molson-Coors, Pfizer, SiTime, Steven Madden, and More

After a brutal sell-off erased Wednesday's rally and dragged the Nasdaq back into correction territory, Wall Street analysts are still moving. Some reversed course on Pfizer, Molson Coors, and BJ's, while others spotted fresh opportunities worth a closer look.

Nov 6, 2026247wallst.com
Pfizer (NYSE:PFE) Hits New 12-Month High on Analyst Upgrade

Pfizer Inc. (NYSE: PFE - Get Free Report) shares reached a new 52-week high on Thursday after Guggenheim raised their price target on the stock from $31.00 to $33.00. Guggenheim currently has a buy rating on the stock. Pfizer traded as high as $31.44 and last traded at $31.2880, with a volume of 8,851,793 shares trading

Nov 6, 2026defenseworld.net
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.

Nov 5, 2026fool.com
Are Your Dividends Safe? 4 Companies Whose Debt Is Competing With the Payout

When a heavily indebted company has to refinance at higher rates, every extra dollar of interest comes out of the same cash pool that funds the dividend. Bondholders have a legal claim on that cash.

Nov 5, 2026247wallst.com
Pfizer Inc. $PFE Shares Newly Acquired by Associated Banc Corp

Associated Banc Corp bought a new stake in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 100,353 shares of the biopharmaceutical company's stock, valued at approximately $2,862,000. Several other hedge funds have also made changes to their positions in the business.

Nov 5, 2026defenseworld.net
Pfizer: The Portfolio Transformation Is Gaining Momentum

Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. PFE delivered a double-beat Q3, raised 2026 guidance, and posted strong non-COVID product growth, offsetting COVID-19 revenue declines. Major acquisitions combined with aggressive cost savings position PFE for strong post-LOE performance and diversification.

Nov 5, 2026seekingalpha.com
Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield

Pfizer delivered Q3 2026 revenue of $16.58B and adjusted EPS of $0.87, beating consensus and raising full-year guidance for the second time. PFE's non-COVID portfolio grew 7% operationally, with launched and acquired products up 32%, offsetting steep COVID-related declines. Management now guides 2026 revenue to $62–$64B and adjusted EPS to $2.95–$3.05, with cost savings and a 5.73% dividend yield well covered by FCF.

Nov 4, 2026seekingalpha.com
Pfizer: 3 Key Takeaways for Long-Term Investors

Pfizer raised 2026 revenue guidance to $62 billion to $64 billion. Launched and acquired products achieved 32% operational revenue growth in Q3.

Nov 4, 2026fool.com
Amazon, Pfizer, Eaton And A Financial Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Amazon.com, Inc. (NASDAQ:AMZN).

Nov 4, 2026benzinga.com
Pfizer Q3 Earnings Call Highlights

Pfizer NYSE: PFE reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts.

Nov 4, 2026marketbeat.com
Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript

Pfizer Inc. ( PFE ) Q3 2026 Earnings Call November 3, 2026 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO Cecile Guegan - Interim CFO & Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Alexandre de Germay - Executive VP & Chief International Commercial Officer Aamir Malik - Executive VP & Chief U.S. Commercial Officer Conference Call Participants Christopher Schott -…

Nov 4, 2026seekingalpha.com
Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market

CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.

Nov 3, 2026youtube.com
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.

Nov 3, 2026247wallst.com
Roth IRA vs. Taxable Account: How Much of $11,400 in Dividends Would You Keep?

Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they file.

Nov 3, 2026247wallst.com